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At last we can now apparently relax in the secure knowledge that long acting 
beta-agonists (LABA) are safe to use in persistent asthma when given in 
combination with inhaled corticosteroid (ICS), on the basis of the FDA 
mandated studies with either fluticasone/salmeterol or budesonide/formoterol 
which showed no increase in serious asthma related events while both 
combinations reduced exacerbations compared to ICS alone1,2. Does this 
mean we can now prescribe ICS/LABA combination inhalers with impunity at 
step 3 and above of asthma guidelines?  
The tenet of asthma therapy is to suppress the underlying inflammatory 
cascade from the top with ICS, which in turn attenuates downstream airway 
smooth muscle twitchiness, resulting in reduced reliever requirement (Figure). 
LABA act primarily on the bottom of the cascade but do not address the 
underlying inflammatory process. The therapeutic conundrum here is that 
using LABA alone may worsen control and only become safe when used in 
conjunction with ICS. LABA are potentially pro-inflammatory ligands acting via 
non-canonical G protein cyclic adenosine monophosphate (Gs-cAMP) 
independent pathways involving extracellular signal regulated kinases and 
beta-arrestin3. For example in antigen sensitized mice who were depleted of 
endogenous adrenaline, exposure to exogenous formoterol resulted in 
restoration of the asthma inflammatory phenotype4. Presumably the salutary 
effects of ICS mitigates the potential pro-inflammatory activity and associated 
adverse effects of LABA.  
LABA may also act via canonical Gs-cAMP pathways on airway inflammatory 
cells to inhibit mediator release and reduce extravascular protein leakage. 
Tolerance rapidly develops to LABA for their canonical effects on 
inflammatory and smooth muscle cells as a consequence of adaptive beta-2 
receptor down regulation and uncoupling of Gs-cAMP, due to prolonged 
receptor occupancy. This explains why chronic dosing with ICS/LABA results 
in predictable loss of protection against bronchoconstrictor stimuli5. Moreover 
there is cross tolerance between LABA and response to salbutamol resulting 
in a blunted reliever response. However a high dose of intravenous 
corticosteroid rapidly reverses beta-2 receptor down regulation and 
associated tolerance in asthmatic patients receiving regular ICS/LABA6.  
Not all patients respond the same in that bronchoprotective tolerance with 
ICS/LABA is greater in approximately 60% of individuals who possess one or 
two copies of the arginine-16 beta-2 receptor polymorphism, being more 
pronounced with formoterol compared to salmeterol reflecting differences in 
intrinsic beta-2 receptor activity7. In asthmatic children taking ICS/LABA the 
risk of an asthma exacerbation is increased by 1.52 fold in relation to each 
copy of the arginine allele8. The 15 % of individuals who have the 
homozygous arginine-16 genotype fare better with fluticasone plus 
montelukast compared with fluticasone plus salmeterol, making a cogent case 
for a more personalised therapy approach9. However, in asthmatic adults 
there was no difference between homozygous arginine/glycine-16 genotypes 
for effects of fluticasone/salmeterol on pulmonary function10. 
So where does that leave us moving forwards with respect to using ICS/LABA 
to achieve optimal asthma control?  It is likely that reduced exacerbations with 
LABA are due to stabilization of airway smooth muscle and improved airway 
geometry as they seem to be devoid of any clinically meaningful in vivo anti-
inflammatory activity. Consequently patients who exhibit features of persistent 
asthmatic inflammation such as raised exhaled breath nitric oxide, blood 
eosinophilia, or persistent airway hyperreactivity should have the dose and 
delivery of ICS optimised either alone or in combination with LABA. In support 
of this therapeutic strategy a higher dose of budesonide alone was found to 
be more effective in reducing severe exacerbations and suppressing 
eosinophils than a lower dose in conjunction with formoterol despite the latter 
producing better pulmonary function, while a higher dose of budesonide with 
formoterol was superior to both11. It may not be possible to extrapolate from 
the somewhat artificial setting of a randomized controlled trial to what 
happens in real life. An observational study found that while adding LABA to 
ICS improved symptoms and reduced reliever requirements, using a higher 
ICS dose was more effective in reducing exacerbations and hospitalisations12. 
However using concomitant ICS/LABA ab initio to improve symptoms may 
help to buy time and improve patient confidence while waiting for the ICS to 
start working.  
An alternative approach is to use flexible dosing with ICS/LABA as single 
inhaler maintenance and reliever therapy (SMART) containing ICS and 
formoterol. Patients who are symptomatic receive extra doses of ICS every 
time they take formoterol as a reliever, so that they end up titrating their own 
anti-inflammatory therapy. This flexible approach results in patients only being 
temporarily exposed to higher ICS doses as for example when challenged by 
triggers such as virus or allergen. Compared to fixed dose ICS/LABA, using 
SMART reduces exacerbations along with lower overall ICS exposure. The 
SMART regimen effectively enforces the patient to adhere to ICS at least 
while they remain symptomatic, and also avoids the possibility of over reliance 
on their salbutamol reliever while stopping their fixed dose ICS/LABA 
combination.  
Perhaps it is somewhat premature to say that the ongoing controversy 
regarding the use of ICS/LABA is now all over. In particular, clinicians need to 
be vigilant to avoid over-prescribing of LABA and at the same time focus on 
suppressing the underlying inflammatory cascade. 
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Figure Legend 
The inflammatory cascade in asthma  
The tenet of asthma therapy is to suppress the top of the inflammatory 
cascade resulting in downstream reduction of airway smooth muscle 
twitchiness thereby reducing reliever requirement. Since LABA only treat the 
bottom of the cascade to stabilize airway smooth muscle, anti-inflammatory 
therapy should be first optimized with ICS +/- LABA to achieve optimal 
control. 
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